z-logo
open-access-imgOpen Access
Real-world effectiveness and safety analysis of carfilzomib–lenalidomide–dexamethasone and carfilzomib–dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis
Author(s) -
Yoshiyuki Onda,
Junya Kanda,
Hitomi Kaneko,
Yuji Shimura,
Shinichi Fuchida,
Aya Nakaya,
Tomoki Itou,
Ryosuke Yamamura,
Hirokazu Tanaka,
Hirohiko Shibayama,
Yutaka Shimazu,
Hitoji Uchiyama,
Satoshi Yoshihara,
Yoko Adachi,
Mitsuhiro Matsuda,
Hitoshi Hanamoto,
Nobuhiko Uoshima,
Satoru Kosugi,
Kensuke Ohta,
Hideo Yagi,
Yuzuru Kanakura,
Itaru Matsumura,
Masayuki Hino,
Shosaku� Nomura,
Chihiro Shimazaki,
Akifumi TakaoriKondo,
Junya Kuroda,
The Kansai Myeloma Forum
Publication year - 2022
Publication title -
therapeutic advances in hematology
Language(s) - English
Resource type - Journals
eISSN - 2040-6215
pISSN - 2040-6207
DOI - 10.1177/20406207221104584
Subject(s) - carfilzomib , medicine , lenalidomide , bortezomib , multiple myeloma , dexamethasone , refractory (planetary science) , oncology , adverse effect , surgery , gastroenterology , physics , astrobiology

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom